JP2020525427A5 - - Google Patents

Download PDF

Info

Publication number
JP2020525427A5
JP2020525427A5 JP2019570466A JP2019570466A JP2020525427A5 JP 2020525427 A5 JP2020525427 A5 JP 2020525427A5 JP 2019570466 A JP2019570466 A JP 2019570466A JP 2019570466 A JP2019570466 A JP 2019570466A JP 2020525427 A5 JP2020525427 A5 JP 2020525427A5
Authority
JP
Japan
Prior art keywords
cancer
combination
composition
inhibitor
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019570466A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020525427A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/038776 external-priority patent/WO2018237158A1/en
Publication of JP2020525427A publication Critical patent/JP2020525427A/ja
Publication of JP2020525427A5 publication Critical patent/JP2020525427A5/ja
Pending legal-status Critical Current

Links

JP2019570466A 2017-06-21 2018-06-21 癌を処置するための方法 Pending JP2020525427A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523091P 2017-06-21 2017-06-21
US62/523,091 2017-06-21
PCT/US2018/038776 WO2018237158A1 (en) 2017-06-21 2018-06-21 Methods for treating cancer

Publications (2)

Publication Number Publication Date
JP2020525427A JP2020525427A (ja) 2020-08-27
JP2020525427A5 true JP2020525427A5 (cg-RX-API-DMAC7.html) 2021-08-12

Family

ID=64737362

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570466A Pending JP2020525427A (ja) 2017-06-21 2018-06-21 癌を処置するための方法

Country Status (6)

Country Link
US (1) US20200138804A1 (cg-RX-API-DMAC7.html)
EP (1) EP3641770A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020525427A (cg-RX-API-DMAC7.html)
CN (1) CN110996952A (cg-RX-API-DMAC7.html)
CA (1) CA3066778A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018237158A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
US10610527B2 (en) 2015-12-22 2020-04-07 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
EP3808748B1 (en) 2016-06-21 2026-05-20 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
JP6994767B2 (ja) 2016-06-21 2022-01-14 エックス4 ファーマシューティカルズ, インコーポレイテッド Cxcr4阻害剤およびその使用
EP3727374A4 (en) * 2017-12-21 2021-11-10 Merck Patent GmbH COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND AN IDO1 INHIBITOR FOR THE TREATMENT OF CANCER
WO2019136451A1 (en) 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
TWI731420B (zh) * 2018-09-27 2021-06-21 大陸商深圳微芯生物科技股份有限公司 具有吲哚胺-2,3-雙加氧酶抑制活性的喹啉衍生物及其製備方法、藥物組合物、聯合用藥物與用途
WO2020186101A1 (en) * 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
WO2021044061A1 (en) * 2019-09-05 2021-03-11 Klinikum Rechts Der Isar Der Technischen Universität München Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent
AU2020260381A1 (en) * 2019-10-30 2021-05-20 Rise Biopharmaceuticals Inc. Pharmaceutical compositions and use thereof for relieving anticancer drug resistance and enhancing sensitivity of anticancer drug
WO2021092593A1 (en) * 2019-11-08 2021-05-14 The University Of North Carolina At Chapel Hill Use of agonists to augment car t function in solid tumors
US20230346772A1 (en) * 2019-12-18 2023-11-02 X4 Pharmaceuticals, Inc. Combination treatments for waldenstrom's macroglobulinemia
CN115515585A (zh) 2020-03-10 2022-12-23 X4 制药有限公司 用于治疗中性粒细胞减少症的方法
TWI855242B (zh) * 2020-03-18 2024-09-11 南韓商Gi醫諾微新股份有限公司 包含含有il-2蛋白與cd80蛋白之融合蛋白及抗癌藥物的用於治療癌症的藥學組成物
WO2021209356A1 (en) * 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
JP2023549086A (ja) * 2020-11-03 2023-11-22 コーナーストーン ファーマシューティカルズ,インコーポレーテッド デビミスタットを使用して胆道癌を治療するための治療法及び組成物
CN113018357A (zh) * 2021-02-08 2021-06-25 湖南农业大学 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途
EP4294399A1 (en) * 2021-02-16 2023-12-27 Ribon Therapeutics Inc. Dosage regimens for parp7 inhibitors
WO2022261382A1 (en) * 2021-06-09 2022-12-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for determining responsiveness to immune checkpoint inhibitors (ici), increasing effectiveness of ici, and treating cancer
US20240285644A1 (en) * 2021-06-17 2024-08-29 Mayo Foundation For Medical Education And Research Assessing and treating prostate cancer
WO2023285681A1 (en) * 2021-07-16 2023-01-19 Spexis Ag Pharmaceutical combinations for treating cancer
IL312155A (en) * 2021-10-15 2024-06-01 Zhenglun Zhu A method for treating cancer
WO2023172640A1 (en) * 2022-03-08 2023-09-14 X4 Pharmaceuticals, Inc. Treatments for single-mutant waldenström's macroglobulinemia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070043012A1 (en) * 2005-08-19 2007-02-22 Bridger Gary J Methods to enhance chemotherapy
UY32306A (es) * 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
EP3030322A2 (en) * 2013-08-05 2016-06-15 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
CA2922398C (en) * 2013-09-12 2023-08-29 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating waldenstrom's macroglobulinemia
WO2016146143A1 (en) * 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
CN114230571B (zh) * 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
EP3405203A4 (en) * 2016-01-22 2019-07-24 X4 Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER

Similar Documents

Publication Publication Date Title
Lei et al. Understanding and targeting resistance mechanisms in cancer
de Bree et al. Pharmacological principles of intraperitoneal and bidirectional chemotherapy
Shaked Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects
Seiwert et al. The concurrent chemoradiation paradigm—general principles
Hosford et al. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways
Ying et al. Developments in metastatic pancreatic cancer: is gemcitabine still the standard?
Owonikoko et al. A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG–ACRIN Cancer Research Group (E2511)
Pipas et al. Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma
Eichholz et al. Anti-angiogenesis therapies: their potential in cancer management
Borazanci et al. Pancreatic cancer:“a riddle wrapped in a mystery inside an enigma”
Sardesai et al. A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer
Kleinberg et al. Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization
Saiki et al. Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance
Li et al. Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma
Antoniou et al. Adjuvant therapy for resectable pancreatic adenocarcinoma: review of the current treatment approaches and future directions
Gridelli et al. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study
Messina et al. Adjuvant chemotherapy in resected bile duct cancer: A systematic review and meta-analysis of randomized trials
Krajnak et al. Metronomic chemotherapy for metastatic breast cancer
Gong et al. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice
Belli et al. Malignant pleural mesothelioma: current treatments and emerging drugs
Reeder-Hayes et al. Clinical trials in triple negative breast cancer
Dębska-Szmich et al. Systemic treatment in triple-negative breast cancer patients—standard and novel approaches
Liu et al. Gemcitabine plus anlotinib is effective and safe compared to gemcitabine plus docetaxel in advanced soft tissue sarcoma
Randazzo et al. SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance
Pogoda et al. Recent advances in the treatment of triple-negative breast cancer